Tamoxifen and raloxifene differ in their functional interactions with aspartate 351 of estrogen receptor α

Molecular Pharmacology

Volumn 70, Issue 2, 2006, Pages 579-588

  Dayan, Guila ^a   Lupien, Mathieu ^b,c   Auger, Anick ^a   Anghel, Silvia I ^a   Rocha, Walter ^a,b   Croisetière, Sébastien ^a   Katzenellenbogen, John A ^d   Mader, Sylvie ^a,b,c  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; RALOXIFENE; TAMOXIFEN; TAMOXIFEN DERIVATIVE; TERTIARY AMINE;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG STRUCTURE; HELA CELL; HUMAN; HUMAN CELL; MUTATION; PRIORITY JOURNAL; PROTEIN INTERACTION; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION; TRANSCRIPTION INITIATION;

EID: 33746256445     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.105.021931     Document Type: Article

References (28)

1. Anghel SI, Perly V, Melancon G, Barsalou A, Chagnon S, Rosenauer A, Miller WH Jr, and Mader S (2000) Aspartate 351 of estrogen receptor α is not crucial for the antagonist activity of antiestrogens. J Biol Chem 275:20867-20872.
2. Belandia B and Parker MG (2003) Nuclear receptors: a rendezvous for chromatin remodeling factors. Cell 114:277-280.
3. Berry M, Metzger D, and Chambon P (1990) Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO (Eur Mol Biol Organ) J 9:2811-2818.
4. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, and Carlquist M (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature (Lond) 389:753-758.
5. Clarke R, Leonessa F, Welch JN, and Skaar TC (2001) Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 53:25-71.
6. Dauvois S, Danielian PS, White R, and Parker MG (1992) Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA 89:4037-4041.
7. Green S and Chambon P (1988) Nuclear receptors enhance our understanding of transcription regulation. Trends Genet 4:309-314.
8. Grese TA, Sluka JP, Bryant HU, Cullinan GJ, Glasebrook AL, Jones CD, Matsumoto K, Palkowitz AD, Sato M, Termine JD, et al. (1997) Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Natl Acad Sci USA 94:14105-14110.
9. Hall JM, McDonnell DP, and Korach KS (2002) Allosteric regulation of estrogen receptor structure, function and coactivator recruitment by different estrogen response elements. Mol Endocrinol 16:469-486.
10. Jordan VC and Gosden B (1982) Importance of the alkylaminoethoxy side-chain for the estrogenic and antiestrogenic actions of tamoxifen and trioxifene in the immature rat uterus. Mol Cell Endocrinol 27:291-306.
11. Katzenellenbogen BS, Choi I, Delage-Mourroux R, Ediger TR, Martini PG, Montano M, Sun J, Weis K, and Katzenellenbogen JA (2000) Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology. J Steroid Biochem Mol Biol 74:279-285.
12. Kuiper G, Enmark E, Pelto-Huikko M, Nilsson S, and Gustafsson JA (1996) Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93:5925-5930.
13. Lednicer D, Lyster SC, and Duncan GW (1967) Mammalian antifertility agents. IV. Basic 3,4-dihydronaphthalenes and 1,2,3,4-tetrahydro-1-naphthols. J Med Chem 10:78-84.
14. Levenson AS and Jordan VC (1998) The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor. Cancer Res 58:1872-1875.
15. Liu H, Lee ES, Deb Los Reyes A, Zapf JW, and Jordan VC (2001) Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex. Cancer Res 61:3632-3639.
16. Liu H, Park WC, Bentrem DJ, McKian KP, Reyes Ade L, Loweth JA, Schafer JM, Zapf JW, and Jordan VC (2002) Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells. J Biol Chem 277:9189-9198.
17. Loven MA, Likhite VS, Choi I, and Nardulli AM (2001) Estrogen response elements alter coactivator recruitment through allosteric modulation of estrogen receptor beta conformation. J Biol Chem 276:45282-45288.
18. MacGregor JI and Jordan VC (1998) Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 50:151-196.
19. MacGregor Schafer J, Liu H, Bentrem DJ, Zapf JW, and Jordan VC (2000) Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351. Cancer Res 60:5097-5105.
20. McDonnell DP, Clemm DL, Hermann T, Goldman ME, and Pike JW (1995) Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 9:659-669.
21. Robertson DW, Katzenellenbogen JA, Hayes JR, and Katzenellenbogen BS (1982) Antiestrogen basicity-activity relationships: a comparison of the estrogen receptor binding and antiuterotrophic potencies of several analogues of (Z)-1,2-diphenyl-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-butene (tamoxifen, Nolvadex) having altered basicity. J Med Chem 25:167-171.
22. Robinson-Rechavi M, Escriva Garcia H, and Laudet V (2003) The nuclear receptor superfamily. J Cell Sci 116:585-586.
23. Rosenfeld MG and Glass CK (2001) Coregulator codes of transcriptional regulation by nuclear receptors. J Biol Chem 276:36865-36868.
24. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, and Greene GL (1998) The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927-937.
25. Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, Pike JW, and McDonnell DP (1994) Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 8:21-30.
26. Voegel JJ, Heine MJ, Tini M, Vivat V, Chambon P, and Gronemeyer H (1998) The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and -independent pathways. EMBO (Eur Mol Biol Organ) J 17:507-519.
27. Wijayaratne AL, Nagel SC, Paige LA, Christensen DJ, Norris JD, Fowlkes DM, and McDonnell DP (1999) Comparative analyses of mechanistic differences among antiestrogens. Endocrinology 140:5828-5840.
28. Wolf DM and Jordan VC (1994) The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res Treat 31:129-138.